Many countries are cautiously emerging from lockdown but life may not completely return to normal until a coronavirus vaccine is found.
After taking over as chief executive of AstraZeneca in 2012, Pascal Soriot sent a team to a global life sciences conference to look for potential drug discovery partners. AstraZeneca’s repeated failure to find new drugs to replace one-time money-spinners as patents expired was not enticing. Seven years on, AstraZeneca has delivered one of the most striking turnrounds in global pharmaceuticals, producing a string of blockbuster cancer drugs that have catapulted it to the industry’s front ranks.
The top British stock market index fell on Thursday after Royal Dutch Shell’s historic dividend cut and Lloyds Banking Group announced big loan-loss provisions.
Vincent Chen wrote that it was “hard to pick winners” among the many Covid-19 vaccine programs, and that a vaccine wouldn’t be widely available until later next year.
Stock market headwinds emerging at resistance.Stock picking is key given uncertainty.Here are the top stocks to buy now.
Q1 was stellar, but COVID-19 boost helped tremendously and we should see a reversal in the coming quarters.COVID-19 is putting Ophthalmology is under a lot pressure, for existing drugs as well as adding to other problems for the recent launch, Beovu.Another r…
Many countries are cautiously emerging from lockdown but life may not completely return to normal until a coronavirus vaccine is found.
If the world is to gain access to a vaccine for COVID-19, there's a good chance it will pass through the doors of Serum Institute of India. Serum Institute, the world's largest manufacturer of vaccines by volume, is working on several candidates for the novel coronavirus - including potentially mass-producing the AstraZeneca/Oxford university one that has garnered global headlines - as well as developing its own. The efforts are partly being shepherded by Umesh Shaligram, the head of research and development.
AstraZeneca PLC continues to diversify revenue growth globally, across all three major therapy areas.AZN continues to benefit from a well-positioned pipeline, with incremental revenue from New Medicines rising by 49% to $1B in Q1 2020.Chinese and emerging mar…
The University of Oxford's COVID-19 vaccine trial has only a 50% chance of success as the coronavirus seems to be fading rapidly in Britain, the professor co-leading the development of the vaccine told the Telegraph newspaper https://bit.ly/2LQTNos. Adrian Hill, director of Oxford's Jenner Institute, which has teamed up with drugmaker AstraZeneca Plc to develop the vaccine, said that an upcoming trial, involving 10,000 volunteers, threatened to return "no result" due to low transmission of COVID-19 in the community. "It's a race against the virus disappearing, and against time", Hill told the British newspaper.
Biotech receives nearly $400 million grant to advance its immunization against the coronavirus Continue reading...
Oxford University's coronavirus vaccine project leader isn't as enthusiastic as you want him to be.
Vaccines are perceived as key to ending the restraints on work and life that have decimated the global economy, and returning to some sense of normalcy.
AstraZeneca CEO says the company will know by June or July whether a coronavirus vaccine it is developing with the University of Oxford will be effective or not.
The Zacks Analyst Blog Highlights: Moderna, Pfizer, BioNTech, Sanofi and GlaxoSmithKline
Inovio has run a lot on speculation about its coronavirus vaccine.This article shows just how likely successful such an Inovio vaccine is.It shows this through two perspectives.
Novavax has begun human trials, and Merck has joined the race with the acquisition of Themis and collaboration with non-profit IAVI.
ADC Therapeutics has filed revised terms for a $125 million U.S. IPO.The firm is developing drug treatment candidates for blood cancers and solid tumors.With a markedly lower price and very strong investor support, the IPO may be worth considering for patient…
Avrobio and Magenta will collaborate on a novel ADC.Adverum reports positive wet AMD data.AstraZeneca's Farxiga is approved.
Goldman Sachs is borrowing the slogan from the British government’s third public service campaign trying to limit the spread of coronavirus — “stay alert, keep distance.”
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 19) * ADC Therapeutics SA (NYSE: ADCT) (IPOed May 15) * Allogene Therapeutics Inc (NASDAQ: ALLO) * Arcturus Therapeuti…
Yahoo Finance’s Brian Sozzi, Alexis Christoforous, and Anjalee Khemlani discuss the latest coronavirus news and the race for a vaccine.
Biotech firm Novavax has entered its coronavirus vaccine in a Phase 1 clinical trial in Australia — the first in the Southern Hemisphere.
Individual stock picking is increasingly important.Continue to concentrate on healthcare and technology.Here are the top stocks to buy now.
Britsh drugmaker AstraZeneca’s stake in Moderna is now worth more than $2 billion after shares in the Massachusetts-based biotech company spiked on hopes for its coronavirus vaccine
Geopolitical rivalries, as well as practical considerations, are emerging as real hurdles in the race for a COVID treatment.
Efforts in formulating a coronavirus vaccine are heating up. These stocks and ETFs look to be the largest beneficiaries.
Novavax's latest progress in the Covid-19 vaccine development brings optimism to the Wall Street.
AZN earnings call for the period ending March 31, 2020.
The University of Oxford, which is partnering with large-cap pharma AstraZeneca plc (NYSE: AZN) to develop a vaccine for SARS-CoV-2, could lead the pack in advancing its vaccine candidate to the next stage.The university is one of the eight companies and inst…
The Zacks Analyst Blog Highlights: Bristol-Myers, Roche, AstraZeneca, Merck and Johnson & Johnson
One thing to start: Bill Ackman has sold his stake in Berkshire Hathaway, he disclosed on Wednesday, saying his hedge fund can seize on opportunities in the market faster than Warren Buffett’s sprawling conglomerate. If Ian Read had his way, AstraZeneca would be a unit of US pharma group Pfizer right now. Luckily for Pascal Soriot, the Frenchman, pictured below, who has run UK-based AstraZeneca since 2012, that didn’t come to pass.
In 2012, Pascal Soriot was appointed CEO of AstraZeneca PLC (LON:AZN). First, this article will compare CEO...
Biotech firm Novavax has entered its coronavirus vaccine in a Phase 1 clinical trial in Australia — the first in the Southern Hemisphere.
As pharmaceutical companies rush to find a vaccine, one doctor says Trump's plan for a new vaccine by the end of the year won't happen.
Q1 was stellar, nevertheless the guidance was confirmed as most of the additional boost from COVID-19 is likely to reverse.Being #1 global vaccine player, we expect GSK to have a strong opportunity in COVID-19 vaccine race.Lower trading multiples are explaine…
A Chinese drugmaker published a paper detailing promising data on a Phase 1 trial of its own Covid-19 vaccine candidate.
British drugmaker AstraZeneca has received more than $1 billion in U.S. funding to accelerate the development of Oxford University’s coronavirus vaccine candidate.